Acenxion
Acenxion Biosystems is developing automated systems for bacteria detection in blood cultures and phenotypic antimicrobial susceptibility testing (AST). Seamlessly fitting into current clinical workflows, Acenxion's scalable AST system reduces the time required for phenotypic testing to 4 hours, enabling informed treatment and rapid use of targeted treatment. Acenxion's technology improves patient outcomes, reduces healthcare costs, and reduces the spread of antibiotic resistance while extending the service life of antibiotics.
Company Ownership:
Socially Disadvantaged
Contact Name:
Roy Swiger
Contact Email:
Website:
https://acenxionbiosystems.com/
City, State – Congressional District:
Kansas City,
KS
–
3
Technology:
Medical Device
Funding:
Allergy and Infectious Diseases (NIAID)
NIH Projects:
NIH RePorter for
Acenxion
Sponsored Event(s):
RESI | 2021
